Bevacizumab attenuates osteosarcoma angiogenesis by suppressing MIAT encapsulated by serum-derived extracellular vesicles and facilitating miR-613-mediated GPR158 inhibition

MLA

Bao-Dong Wang, et al. “Bevacizumab Attenuates Osteosarcoma Angiogenesis by Suppressing MIAT Encapsulated by Serum-Derived Extracellular Vesicles and Facilitating MiR-613-Mediated GPR158 Inhibition.” Cell Death and Disease, vol. 13, no. 3, Mar. 2022, pp. 1–10. EBSCOhost, https://doi.org/10.1038/s41419-022-04620-3.

APA

Bao-Dong Wang, Xiao-Jun Yu, Ji-Chun Hou, Bo Fu, Hao Zheng, Qi-Kun Liu, Shan-Xi Wang, Zheng-Gang Bi, & Yang Cao. (2022). Bevacizumab attenuates osteosarcoma angiogenesis by suppressing MIAT encapsulated by serum-derived extracellular vesicles and facilitating miR-613-mediated GPR158 inhibition. Cell Death and Disease, 13(3), 1–10. https://doi.org/10.1038/s41419-022-04620-3

Chicago

Bao-Dong Wang, Xiao-Jun Yu, Ji-Chun Hou, Bo Fu, Hao Zheng, Qi-Kun Liu, Shan-Xi Wang, Zheng-Gang Bi, and Yang Cao. 2022. “Bevacizumab Attenuates Osteosarcoma Angiogenesis by Suppressing MIAT Encapsulated by Serum-Derived Extracellular Vesicles and Facilitating MiR-613-Mediated GPR158 Inhibition.” Cell Death and Disease 13 (3): 1–10. doi:10.1038/s41419-022-04620-3.